Jazz Pharmaceuticals, a pharmaceutical company, has agreed to acquire Redx Pharma's pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Financial terms were not disclosed. "There is the potential to address RAS driven tumors. We look forward to advancing the pan-RAF inhibitor program that is part of a novel class of next generation precision oncology drugs and is highly complementary to our growing R&D portfolio of early-stage, innovative, hematology/oncology therapies." Robert Iannone, Jazz Pharmaceuticals executive vice president.